Yongin, South Korea

Jin Sun Park

This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Vivozon, Inc.. Active years: 2024-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jin Sun Park. Retrieved from https://idiyas.com/inventor/jin-sun-park-hho3ebpn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0


Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2024-2025

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Jin Sun Park: The Dual Modulator Patent

Introduction

Jin Sun Park, a dedicated inventor based in Yongin-si, South Korea, has made significant contributions to the field of pharmacology. His innovative work focuses on the development of compounds that modulate various receptors, which could lead to advancements in treating pain and other medical conditions.

Latest Patents

Among his notable achievements, Jin Sun Park holds a patent for a "Dual modulator of mGluR5 and 5-HT2A receptor." This invention is particularly groundbreaking as it discloses a compound that acts as a modulator of the mGluR5 receptor while simultaneously functioning as an antagonist for the 5-HT2A receptor. This dual action could provide a new therapeutic approach in pain management, indicating the potential for significant advancements in treatment efficacy.

Career Highlights

Currently, Jin Sun Park is associated with Vivozon, Inc., where he continues to engage in innovative research aimed at enhancing therapeutic interventions for different health conditions. His position at this reputable organization underscores his role as a key figure in the development of novel pharmacological solutions.

Collaborations

Throughout his career, Jin Sun Park has collaborated with talented colleagues, including Dae Kyu Choi and Hyo Jin Kim. Their combined expertise fosters an innovative environment that encourages the exploration of new ideas and the advancement of scientific research.

Conclusion

Jin Sun Park's work exemplifies the spirit of innovation within the pharmaceutical industry. His patent related to the dual modulator of mGluR5 and 5-HT2A receptors marks a significant step forward in therapeutic options for pain management. As he continues to work at Vivozon, Inc., there is great anticipation for the future developments he and his team will bring to the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…